The phenotype of less severe BrCa subtypes, such as Luminal A, Luminal B, and HER2-enriched types are well characterized, which has led to the discovery of drug therapies that have increased survival time for these patient groups. The gene discussed is ERBB2; the disease is invasive breast carcinoma.